Biotechnology startup Eleusis is exploring sub-perceptual levels of LSD as a potential treatment for Alzheimer’s disease. Company CEO Shlomi Raz explains their short and longer-term strategies.
This post was created with our nice and easy submission form. Create your post!
Comments
Loading…